Neha Subhash Nilawad,
- Student, Department of Bioinformatics, Institute of Bioscience and Technology, MGM University Chhatrapati Sambhajinagar, Maharashtra, India
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_114023’);});Edit Abstract & Keyword
Objective: Muscle feebleness and exhaustion derived from a disruption in neuromuscular transference are hallmarks of the crippling autoimmune disease myasthenia gravis (MG).The drawbacks of the current MG therapy options are frequently partial efficacy and adverse effects. To investigate the potential of phytochemicals in MG control, in this work, we integrated molecular docking with ADME (Absorption, Distribution, Metabolism, and Excretion) analysis using a computer method. We identified molecules exhibiting favourable interactions with key molecular targets implicated in MG pathophysiology, such as muscle-specific kinase (MuSK), nicotinic acetylcholine receptors (nAChRs), and acetylcholinesterase (AChE). Explore the natural substances called phytochemicals that are derived from plants and may have therapeutic uses in treating a variety of ailments, including autoimmune disorders. This has become more and more popular in the past few years. Methods: Theoretical Methodology: This study aims to explore the potential of phytochemicals from the Cassia Fistula medicinal plant for the treatment of Myasthenia Gravis (MG) through a multi-step computational approach. Firstly, the top five phytochemicals from Cassia Fistula will be selected based on literature review and computational screening. These compounds will then undergo molecular docking onto the active site of the muscle-specific kinase (MuSK) protein (PDB ID: 1LUF) using PyRx software to predict their binding affinities and interactions. Following this, ADME (Absorption, Distribution, Metabolism, and Excretion) analysis will be conducted to evaluate the pharmacokinetic properties of the docked compounds, including bioavailability and toxicity. In order to identify possible lead compounds for additional experimental validation, Biovia software will be used to visualize protein-ligand interactions. This integrated approach holds promise for the discovery of novel phytochemical-based therapeutics for MG treatment. Result: Molecular docking investigations indicated that Rhein, Chrysophanic Acid, Aromadendrin, Aloe emodin and Anthraquinone were in the ligands with the lowest binding affinities to the targeted proteins. Conclusion: In conclusion, we have effectively discovered phytochemicals with promise for treating Myasthenia Gravis (MG) by our molecular docking and ADME analysis technique utilizing Biovia and PyRx. Using computational screening, we found phytochemicals with good pharmacokinetic characteristics and a substantial binding affinity to MG-related target proteins. These results demonstrate the possibility of using natural substances as MG treatment alternatives. In order to determine these compounds’ safety and efficacy and to prepare the way for the creation of novel MG therapies based on phytochemicals, more experimental validation of these compounds is necessary.
Keywords: Myasthenia Gravis, phytochemicals, molecular docking, ADME analysis, neuromuscular transmission, precision medicine
[This article belongs to International Journal of Molecular Biotechnological Research (ijmbr)]
Neha Subhash Nilawad. Exploring Potential Phytochemicals for Myasthenia Gravis Treatment: A Molecular Docking and ADME Analysis Approach. International Journal of Molecular Biotechnological Research. 2024; 02(02):-.
Neha Subhash Nilawad. Exploring Potential Phytochemicals for Myasthenia Gravis Treatment: A Molecular Docking and ADME Analysis Approach. International Journal of Molecular Biotechnological Research. 2024; 02(02):-. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_114023’);});Edit
1. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgraduate medical journal. 2004 Dec;80(950):690-700. 2. Eldaabossi S, Alrashdan M, Aljanobi G, Warsha N, Elhassan SA, Mahdi W, Farouk A, Taha A, Qabil A, Maklad S, Nabway U. A rare association: Obesity hypoventilation syndrome with myasthenia gravis and systemic lupus erythematosus, case report. Respiratory Medicine Case Reports. 2023 Jan 1;44:101848. 3. Cao M, Koneczny I, Vincent A. Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment. Frontiers in Molecular Neuroscience. 2020 Sep 2;13:159. 4. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune diseases. 2012;2012(1):874680. 5. Marsteller HB. The first American case of myasthenia gravis. Archives of neurology. 1988 Feb 1;45(2):185-7. 6. Somnier FE. Myasthenia gravis-Occurrence, failure in neuromuscular transmission, clinical implementation of anti-AChR antibodies, and therapeutic progress. Danish Medical Bulletin. 1996 Feb 1;43(1):1-0. 7. Evoli A. Acquired myasthenia gravis in childhood. Current opinion in neurology. 2010 Oct 1;23(5):536-40. 8. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E. Response to therapy in myasthenia gravis with anti‐MuSK antibodies. Annals of the New York Academy of Sciences. 2008 Jun;1132(1):76-83. 9. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards1. The Annals of thoracic surgery. 2000 Jul 1;70(1):327-34. 10. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton‐Jones D, Melms A, Verschuuren J, Horge HW. Guidelines for treatment of autoimmune neuromuscular transmission disorders. European journal of neurology. 2010 Jul;17(7):893-902. 11. Elovaara I, Apostolski S, Van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, Van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology. 2008 Sep;15(9):893-908. 12. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity. 2010 Aug 1;43(5-6):371-9. 13. Matsumoto Y, Matsuo H, Sakuma H, Park IK, Tsukada Y, Kohyama K, Kondo T, Kotorii S, Shibuya N. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. The Journal of Immunology. 2006 Apr 15;176(8):5100-7. 14. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RB, Aparna SR, Mangalapandi P, Samal A. IMPPAT: A curated database of I ndian M edicinal P lants, P hytochemistry A nd T herapeutics. Scientific reports. 2018 Mar 12;8(1):4329. 15. Saldívar-González FI, Huerta-García CS, Medina-Franco JL. Chemoinformatics-based enumeration of chemical libraries: a tutorial. Journal of cheminformatics. 2020 Oct 27;12(1):64. 16. Chen SC, Chen T. Retrieval of 3D protein structures. InProceedings. International Conference on Image Processing 2002 Sep 22 (Vol. 3, pp. 933-936). IEEE. 17. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic acids research. 2003 Jul 1;31(13):3381-5. 18. Adrees S, Imtiaz A, Yaseen A, Irfan Fareed M, Anwar W, Ashraf A, Shabbir RM, Andlib S, Hussain M, Tariq A, Mateen RM. In-silico analysis of potential anticancer drug for NEK7 and PPP1CA proteins overexpressed in pancreatic ductal adenocarcinoma. Journal of Biomolecular Structure and Dynamics. 2024 Feb 26:1-7. 19. Ahmad I, Khan H, Serdaroğlu G. Physicochemical properties, drug likeness, ADMET, DFT studies, and in vitro antioxidant activity of oxindole derivatives. Computational Biology and Chemistry. 2023 Jun 1;104:107861. 20. Morris GM, Lim-Wilby M. Molecular docking. Molecular modeling of proteins. 2008:365-82. 21. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Chemical biology: methods and protocols. 2015:243-50. 22. Sharma S, Sharma A, Gupta U. Molecular Docking studies on the Anti-fungal activity of Allium sativum (Garlic) against Mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Annals of Antivirals and Antiretrovirals. 2021 Nov 12;5(1):028-32. 23. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins. 1992 Apr;12(4):345-64. doi: 10.1002/prot.340120407. PMID: 1579569. (Ramchandran)